Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Public ClinicalTrials.gov record NCT03424603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Study identification
- NCT ID
- NCT03424603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- STRO-001 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2018
- Primary completion
- Feb 14, 2024
- Completion
- Mar 14, 2024
- Last update posted
- Jun 10, 2024
2018 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Arizona Oncology Associates, PC--HOPE Division | Tucson | Arizona | 85711 | — |
| City of Hope Medical Center | Duarte | California | 91010 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Univeristy of California San Francisco HDF Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Cancer Center | Fairway | Kansas | 66205 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Weill Cornell Medicine | New York | New York | 10065 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| UT Health San Antonio | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| West Virginia University | Morgantown | West Virginia | 26505 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03424603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03424603 live on ClinicalTrials.gov.